EGFR and non-small cell lung carcinoma: Given the critical role of EGFR in the development and progression of NSCLC and considering that aberrant EGFR signaling is an eminent feature for EGFR‐TKI resistance in NSCLC,[17] we wanted to search for potential targets that selectively modulate EGFR activity for possible more efficient treatments of NSCLC.